Ortega J A, Nesbit M E, Donaldson M H, Hittle R E, Weiner J, Karon M, Hammond D
Cancer Res. 1977 Feb;37(2):535-40.
L-Asparaginase was added to vincristine and prednisone for induction of first remission in 815 children with acute lymphocytic or acute undifferentiated leukemia. This combination resulted in an overall remission rate of 93%. The addition of L-asparaginse to the standard induction regimen using prednisone and vincristine did not significantly increase the morbidity or mortality rate during the induction period. The most common side effect was transient L-asparaginase-induced hyperglycemia. The safe administration of L-asparaginase i.m. and the dose efficacy of 6000 I.U./sq m were confirmed. For these reasons, L-asparaginase should be combined with vincristine and prednisone for the initial induction of children with acute lymphocytic or acute undifferentiated leukemia.
在815例急性淋巴细胞白血病或急性未分化白血病患儿诱导首次缓解时，将左旋门冬酰胺酶添加到长春新碱和泼尼松中。这种联合用药使总体缓解率达到了93%。在使用泼尼松和长春新碱的标准诱导方案中添加左旋门冬酰胺酶，并未显著增加诱导期的发病率或死亡率。最常见的副作用是左旋门冬酰胺酶诱导的短暂高血糖。证实了左旋门冬酰胺酶肌内注射的安全给药以及6000国际单位/平方米的剂量疗效。基于这些原因，左旋门冬酰胺酶应与长春新碱和泼尼松联合用于急性淋巴细胞白血病或急性未分化白血病患儿的初始诱导治疗。
